Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Macfadden, Wayne ^a   Adler, Caleb M ^b   Turkoz, Ibrahim ^c   Haskins, John T ^c   Turner, Norris ^a   Alphs, Larry ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE RIGIDITY; OPEN STUDY; RELAPSE; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; WEIGHT GAIN; YOUNG MANIA RATING SCALE; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MOOD DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; MOOD DISORDERS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RISPERIDONE;

EID: 80055009940     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-171     Document Type: Article

References (23)

1. Keck PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998, 155:646-652.
2. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Discord 2003, 73:123-131.
3. Bowden CL. Bipolar disorder and work loss. Am J Manag Care 2005, 11:S91-S94.
4. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006, 163:1561-1568. 10.1176/appi.ajp.163.9.1561, 1924724, 16946181.
5. Laxman KE, Lovibond KS, Hassan MK. Impact of bipolar disorder in employed populations. Am J Manag Care 2008, 14:757-764.
6. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Wagner KD, Perlis RH. Practice Guideline for the Treatment of Patients With Bipolar Disorder. 2002, 1-82. Second.
7. Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005, 19:557-569. 10.2165/00023210-200519070-00001, 15984894.
8. Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Discord 2000, 61:13-22.
9. Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME, Sachs GS. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010, 71:296-303. 10.4088/JCP.09m05514yel, 20331931.
10. Martinez-Aran A, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C, Leboyer M, Henry C, Goodwin GM, Gonzalez-Pinto A, Cruz N, Sanchez-Moreno J, Vieta E. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009, 70:1017-1023. 10.4088/JCP.08m04408, 19497247.
11. Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Discord 2010, 127:77-83.
12. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health-Syst Pharm 2009, 66:358-365. 10.2146/ajhp080374, 19202045.
13. Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 1995, 10:65-71.
14. Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry 2008, 9:219-224. 10.1080/15622970701530917, 18609430.
15. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Dis 2009, 11:827-839.
16. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010, 68:156-162. 10.1016/j.biopsych.2010.01.015, 20227682.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435. 10.1192/bjp.133.5.429, 728692.
19. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171. 10.1016/S0165-1781(97)00123-6, 9481807.
20. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995, 166:654-659. 10.1192/bjp.166.5.654, 7620753.
21. Montgomery S, Vieta E, Sulaiman AH, Cordoba R, Huberlant B, Schreiner A, Martinez G. Randomized, double-blind, placebo-controlled study of risperidone long-acting injectable in relapse prevention in patients with bipolar I disorder. Presented at the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany 2010,
22. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, Comes M, Torrent C, Kapczinski F, Vieta E. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010,
23. Riperdal® Consta® [prescribing information]. 2010, Titusville, NJ: Ortho-McNeil Janssen.